Systemic lupus erythematosus and increased risk to develop B cell malignancies: Role of the p200-family proteins

Immunology Letters

Volumn 133, Issue 1, 2010, Pages 1-5

  Veeranki, Sudhakar ^a   Choubey, Divaker ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; B cell malignancies; Interferons; P200 family; P53; Sex bias; SLE

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BETA INTERFERON; CHEMOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON INDUCIBLE PROTEIN 202; INTERLEUKIN 6; ONCOPROTEIN; PROLINE RICH PROTEIN; PROTEIN P200; PROTEIN P50; PROTEIN P52; PROTEIN P53; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; B LYMPHOCYTE; CANCER RISK; CARCINOGENESIS; DNA DAMAGE; GENE DELETION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HOMOZYGOSITY; HUMAN; INHIBITION KINETICS; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, B-CELL; MUTATION; NUCLEAR PROTEINS; PHOSPHOPROTEINS; RISK; SEX FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955853897     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.06.008     Document Type: Review

References (68)

1. Kotzin B.L. Systemic lupus erythematosus. Cell 1996, 85:303-306.
2. Crispín J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
3. Pisetsky D.S. The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008, 8:69-72.
4. Baccala R., Kono D.H., Theofilopoulos A.N. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005, 204:9-26.
5. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336.
6. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990.
7. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
8. Su L., David M. Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 1999, 162:6317-6321.
9. Gayed M., Bernatsky S., Ramsey-Goldman R., Clarke A., Gordon C. Lupus and cancer. Lupus 2009, 18:479-485.
10. Bernatsky S., Ramsey-Goldman R., Clarke A.E. Malignancy in systemic lupus erythematosus: what have we learned?. Best Pract Res Clin Rheumatol 2009, 23:539-547.
11. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788.
12. Mellors R.C. Autoimmune disease in NZB-Bl mice. II. Autoimmunity and malignant lymphoma. Blood 1966, 27:435-448.
13. 1 mice. J Exp Med 1974, 140:1547-1558.
14. Scaglione B.J., Salerno E., Balan M., Coffman F., Landgraf P., Abbasi F., et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 2007, 139:645-657.
15. Harris S.L., Levine A.J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
16. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003, 10:431-442.
17. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K., et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997, 337:529-534.
18. Dolcetti R., Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol 1996, (Suppl. 14):S3-S13.
19. Buttgereit P., Schakowski F., Märten A., Brand K., Renoth S., Ziske C., et al. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. Cancer Gene Ther 2001, 8:430-439.
20. Rathmell J.C., Thompson C.B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 2002, (109 Suppl.):S97-S107.
21. Miret C., Molina R., Filella X., Garcia-Carrasco M., Claver G., Ingelmo M., et al. Relationship of p53 with other oncogenes, cytokines and systemic lupus erythematosus activity. Tumour Biol 2003, 24:185-188.
22. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-3257.
23. D'Souza S., Xin H., Walter S., Choubey D. The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression. J Biol Chem 2001, 276:298-305.
24. Chipuk J.E., Green D.R. Cytoplasmic p53: bax and forward. Cell Cycle 2004, 3:429-431.
25. Baptiste N., Prives C. p53 in the cytoplasm: a question of overkill?. Cell 2004, 116:487-489.
26. Erster S., Mihara M., Kim R.H., Petrenko O., Moll U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004, 24:6728-6741.
27. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., et al. Integration of interferon-alpha/beta signaling to p53 responses in tumor suppression and antiviral defense. Nature 2003, 424:516-523.
28. Kuan A.P., Cohen P.L. p53 is required for spontaneous autoantibody production in B6/lpr lupus mice. Eur J Immunol 2005, 35:1653-1660.
29. Salvador J.M., Hollander M.C., Nguyen A.T., Kopp J.B., Barisoni L., Moore J.K., et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 2002, 16:499-508.
30. Balomenos D., Martín-Caballero J., García M.I., Prieto I., Flores J.M., Serrano M., et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 2000, 6:171-176.
31. Zheng S.J., Lamhamedi-Cherradi S.E., Wang P., Xu L., Chen Y.H. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 2005, 54:1423-1428.
32. Murphy M.E. The thousand doors that lead to death: p53-dependent repression and apoptosis. Cancer Biol Ther 2003, 2:381-382.
33. Venot C., Maratrat M., Dureuil C., Conseiller E., Bracco L., Debussche L. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J 1998, 17:4668-4679.
34. Slatter T.L., Ganesan P., Holzhauer C., Mehta R., Rubio C., Williams G., et al. p53-mediated apoptosis prevents the accumulation of progenitor B cells and B-cell tumors. Cell Death Differ 2010, 17:540-550.
35. Choubey D., Kotzin B.L. Interferon-inducible p202 in the susceptibility to systemic lupus. Front Biosci 2002, 7:e252-e262.
36. Choubey D., Panchanathan R. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett 2008, 119:32-41.
37. Wang H., Chatterjee G., Meyer J.J., Liu C.J., Manjunath N.A., Bray-Ward P., et al. Characteristics of three homologous 202 genes (Ifi202a, Ifi202b, and Ifi202c) from the murine interferon-activatable gene 200-cluster. Genomics 1999, 60:281-294.
38. Albrecht M., Choubey D., Lengauer T. The HIN domain of IFI-200 proteins consists of two OB-folds. Biochem Biophys Res Commun 2005, 327:679-687.
39. Choubey D., Duan X., Dickerson E., Ponomareva L., Panchanathan R., Shen H., et al. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res 2010, 30(February):371-380.
40. Panchanathan R., Shen H., Bupp M.G., Gould K.A., Choubey D. Female and male sex hormones differentially regulate expression of Ifi202, an interferon-inducible lupus susceptibility gene within the Nba2 interval. J Immunol 2009, 183:7031-7038.
41. Rozzo S.J., Allard J.D., Choubey D., Vyse T.J., Izui S., Peltz G., et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001, 15:435-443.
42. Choubey D., Pramanik R., Xin H. Sub-cellular localization and mechanisms of nucleocytoplasmic distribution of p202, an interferon-inducible candidate for lupus susceptibility. FEBS Lett 2003, 553:245-249.
43. Roberts T.L., Idris A., Dunn J.A., Kelly G.M., Burnton C.M., Hodgson S., et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009, 323:1057-1060.
44. Choubey D., Panchanathan R., Shen H., Duan X. Comment on " Development of murine lupus involves the combined genetic contribution of the SLAM and FcγR intervals within the Nba2 autoimmune susceptibility locus" J Immunol 2010, 184:4051-4052.
45. Choubey D., Lengyel P. Interferon action: cytoplasmic and nuclear localization of the interferon-inducible 52-kDa protein that is encoded by the Ifi200-gene from the gene 200-cluster. J Interferon Res 1993, 13:43-52.
46. Xin H., D'Souza S., Jorgensen T.N., Vaughan A.T., Lengyel P., Kotzin B.L., et al. Increased expression of Ifi202, an IFN-activatable gene, in B6.Nba2 lupus susceptible mice inhibits p53-mediated apoptosis. J Immunol 2006, 176(May):5863-5870.
47. Huxford T., Malek S., Ghosh G. Structure and mechanism in NF-kappa B/I kappa B signaling. Cold Spring Harb Symp Quant Biol 1999, 64:533-540.
48. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
49. Do R.K., Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002, 13:19-25.
50. Laâbi Y., Strasser A. Immunology. Lymphocyte survival - ignorance is BLys. Science 2000, 289:883-884.
51. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
52. Enzler T., Bonizzi G., Silverman G.J., Otero D.C., Widhopf G.F., Anzelon-Mills A., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
53. Wu T., Qin X., Kurepa Z., Kumar K.R., Liu K., Kanta H., et al. Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007, 117:2186-2196.
54. Kalergis A.M., Iruretagoyena M.I., Barrientos M.J., González P.A., Herrada A.A., Leiva E.D., et al. Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus. Immunology 2009, 128(1 Suppl.):e306-e314.
55. Dai R., Phillips R.A., Ahmed S.A. Despite inhibition of nuclear localization of NF-kappa B p65, c-Rel, and RelB, 17-beta estradiol up-regulates NF-kappa B signaling in mouse splenocytes: the potential role of Bcl-3. J Immunol 2007, 179:1776-1783.
56. Yang C.H., Murti A., Pfeffer L.M. Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival. J Biol Chem 2005, 280:31530-31536.
57. Min W., Ghosh S., Lengyel P. The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-kappa B, c-Fos, and c-Jun activities. Mol Cell Biol 1996, 16:359-368.
58. Ma X.Y., Wang H., Ding B., Zhong H., Ghosh S., Lengyel P. The interferon-inducible p202a protein modulates NF-κB activity by inhibiting the binding to DNA of p50/p65 heterodimers and p65 homodimers while enhancing the binding of p50 homodimers. J Biol Chem 2003, 278:23008-23019.
59. 1 mice, is a positive regulator for NF-kappaB activation in dendritic cells. Int Immunol 2007, 19:935-942.
60. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897.
61. Feng B., Cheng S., Pear W.S., Liou H.C. NF-kB inhibitor blocks B cell development at two checkpoints. Med Immunol 2004, 3:1-16.
62. Choubey D., Deka R., Ho S.M. Interferon-inducible IFI16 protein in human cancers and autoimmune diseases. Front Biosci 2008, 13:598-608.
63. Johnstone R.W., Wei W., Greenway A., Trapani J.A. Functional interaction between 53p and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000, 19:6033-6042.
64. Kwak J.C., Ongusaha P.P., Ouchi T., Lee S.W. IFI16 as a negative regulator in the regulation of p53 and p21(Waf1). J Biol Chem 2003, 278:40899-40904.
65. Song L.L., Alimirah F., Panchanathan R., Xin H., Choubey D. Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53. Mol Cancer Res 2008, 6:1732-1741.
66. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., Song G.G. The functional p53 codon 72 polymorphism is associated with systemic lupus erythematosus. Lupus 2005, 14:842-845.
67. Hoshida Y., Hongyo T., Xu J.X., Sasaki T., Tomita Y., Nomura T., et al. TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases. Oncology 2005, 69:175-183.
68. Caposio P., Gugliesi F., Zannetti C., Sponza S., Mondini M., Medico E., et al. A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells. J Biol Chem 2007, 282:33515-33529.